ISSN: 0959-8049

European Journal of Cancer Q1 Unclaimed

Elsevier Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

European Journal of Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 235. Journal with a Single blind Peer Review review system, and It has a price of 2655 €. The scope of the journal is focused on Cancer, Oncology, Clinical Oncology, Medicine. It has an SJR impact factor of 2,898 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,898.

European Journal of Cancer focuses its scope in these topics and keywords: cancer, patients, cell, advanced, tumour, colorectal, lung, carcinoma, therapy, cd, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1) Oncology (Q1)

Price

2655 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

2,898

SJR Impact factor

235

H Index

806

Total Docs (Last Year)

1354

Total Docs (3 years)

15826

Total Refs

9192

Total Cites (3 years)

1085

Citable Docs (3 years)

6.15

Cites/Doc (2 years)

19.64

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

CA - A Cancer Journal for Clinicians Q1
Molecular Cancer Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

I.4 Effects of anti-oestrogens on insulin-like growth factor (IGF-I) physiology systemically and in the uterus

Maintaining abstinence from cigarette smoking: effectiveness of group counselling and factors predicting outcome

74 O - Selective anti-leukemic potential of HLA-incompatible bone marrow transplants

Surveillance for stage I testicular germ cell tumours

Chromophilic renal cell carcinoma: Characterization of four permanent cell lines

Is there a standard adjuvant treatment for rectal cancer?

Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue

Is the time interval between diagnosis and radiation treatment an important factor in brain metastases?

The use of national registers of radiation exposure in occupational radiation risk assessment

Apoptosis of Ovarian carcinoma cells (N1) by TNF and it's possible targets

Time trends in ovarian cancer mortality in Europe (1955-1993)

Bile duct stents: Is there an increased rate of complications in patients receiving chemotherapy?

SHOW MORE ARTICLES

All-trans retinoic acid enhances gap junctional intercellular communication among renal epithelial cells in vitro treated with renal carcinogens

Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy

163 O - Aortic infuslon (ADM, MMC, CDDP) and stop-flow (MMC, ADM) for systemically pretreated and progresslve FLGO III c and IV ovarian cancer-45 patients

Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer

A novel herpes vector for the high efficiency transduction of primary hematopoietic cells

nm23 Protein expression in larynx cancer and the relationship with metastasis

Cancer information: a cost-effective intervention

A high pretreatment serum level of VEGF is associated with poor outcome in small cell lung cancer

26 P - Monitoring of neurotoxicity of taxanes

A Glimpse of the Future. New Directions in the Treatment of Colorectal Cancer

13-Cis-retinoic acid and alphainterferon in advanced squamous cell cancer of the oesophagus

The role of desmosomal glycoproteins in the adhesion & invasion of human breast cancer cells